Corxel Pharmaceuticals closed a $287 million Series D round to push its oral small‑molecule GLP‑1 receptor agonist CX‑11 through Phase II and toward global development. The financing will support ongoing U.S. Phase II obesity trials, a planned global Phase II in type 2 diabetes, preparations for Phase III and additional cardiometabolic programs. Management said the capital will accelerate clinical timelines and expand regulatory and commercial planning for an oral GLP‑1 that the company positions as competitive with injectable therapies.